Introduction
Bleeding is a well-known complication of patients with essential thrombocythemia (ET), since the first description of this disorder in 1934, termed 'hemorrhagic thrombocythemia'. 1 Nowadays, 5-10% of ET patients are expected to suffer from a major hemorrhagic complication, particularly gastrointestinal and urogenital, but also intracranial. 2, 3 Patients at risk are those with very elevated platelet count, often associated with an acquired von Willebrand disease, previous bleeding events and concomitant use of antithrombotic agents, especially aspirin. 4 However, current knowledge is based on a limited number of clinical studies, which included heterogeneous groups of patients diagnosed with different classification systems, established by the Polycythemia Vera Study Group (PVSG), 5 and then by the World Health Organization (WHO). 6 In 2008, the WHO provided updated guidelines for the diagnosis of ET and its distinction from early/prefibrotic primary myelofibrosis (PMF). 7 In a recent international study of 1104 patients previously diagnosed and treated as ET, a central bone marrow review revealed the inadvertent inclusion of 180 cases with early/prefibrotic PMF. 8 The latter group of patients displayed significantly worse overall, leukemiafree and MF-free survival, but no difference in thrombotic complications. 9 In the present study, we further analyzed this large cohort of patients, focusing on bleeding, with the aims to update prevalence and risk factors, and to provide clinical information for the management of this complication in patients with strictly defined WHO-ET versus those with early PMF.
Patients and methods
Clinicians and pathologists from seven international centers of excellence for myeloproliferative neoplasms convened to create a clinicopathologic database of 1104 patients previously diagnosed and treated as ET. 8, 9 The study was approved by the institutional review board of each institution. Study eligibility criteria included availability of treatment-naïve bone marrow specimens obtained within 1 year of diagnosis. All bone marrows subsequently underwent a central re-review by one of the authors (JT), of the WHO chapters on diagnostic criteria for ET, polycythemia vera and PMF. The central histology review by JT was completely blinded to the outcome data, which was analyzed after the completion of the histopathological review. Diagnosis was confirmed as ET in 891 patients (81%), and revised to early/prefibrotic PMF in 180 (16%); 33 cases were not evaluable. Median follow-up from time of diagnosis was 6.2 years (range, 0-27) for ET and 7 years (range, 0-27.2) for early/ prefibrotic PMF (P ¼ 0.3). During this period, 87 (10%) patients with ET and 40 (22%) with early/prefibrotic PMF had died (P ¼ 0.0002). Cytoreductive therapy was instituted in 507 (57%) patients with ET and 123 (68%) with early/prefibrotic PMF (P ¼ 0.005). Low-dose aspirin (70-100 mg/day) was given as primary and secondary prophylaxis according to medical need.
For the purpose of the current study, we considered only major bleeding events, defined as a symptomatic hemorrhage in a critical organ or an overt hemorrhage requiring transfusion or associated with a hemoglobin decrease 420 g/l without transfusion. All statistical analyses considered parameters at the time of initial diagnosis, and outcomes of interest were reported as incidence rates (IR) per 100 patients per year (% pts/ year). Cox proportional hazard regression model was used for multivariable analysis, adjusting for diagnostic group (when applicable), age X60 years, gender, platelet and white blood cell (WBC) counts, JAK2V617F mutational status, splenomegaly, previous thrombosis, previous bleeding and need of cytoreductive therapy and aspirin (70-100 mg/daily) during follow-up. Interactions between aspirin use and diagnostic group, standard risk factors for thrombosis, and PLT and WBC count were also tested. P-values less than 0.05 were considered significant.
Results
Main characteristics of patients with WHO-ET versus those with early PMF are shown in Table 1 . A significantly higher number of patients with early PMF showed leukocytosis 411 Â 10 9 /l and thrombocytosis 41000 Â 10 9 /l at diagnosis and major bleeding events during the follow-up (12% vs 6%, P ¼ 0.009). The incidence of major bleeding was 1.39% pts/year in early PMF versus 0.79% in WHO-ET, with an IR ratio (IRR) of 1.76 (P ¼ 0.039). In both groups, the more frequent site of bleeding was the gastrointestinal tract. Low-dose aspirin prophylaxis was similarly distributed in the two groups. On the other hand, the fraction of 185 ET patients (21%) with an increased WBC count revealed a bleeding rate of 0.98% pts/year, which was nearly the same (0.99% pts/year) with that of early PMF with normal leukocyte count (o11 Â 10 9 /l). The higher rate was that of early PMF with leukocytosis (2.0% pts/year). Table 2 shows the results of multivariable analysis of risk factors for major bleeding. The diagnosis of early PMF remained an independent predictor of hemorrhagic complications, as well as WBC count at diagnosis, previous bleeding and low-dose aspirin use. The analysis restricted to patients with WHO-ET confirmed previous hemorrhage (P ¼ 0.043; hazard ratio 1.92) and aspirin (P ¼ 0.027; hazard ratio 2.24) as independent risk factors.
To assess the cumulative effect of aspirin assumption with other variables, a series of interaction analyses were performed according to WHO diagnosis (ET vs early PMF; Table 3 ). A relevant interactive effect was observed in WHO-ET when the drug was given to the high-risk category including elderly patients, when platelet count exceeded 1000 Â 10 9 /l and WBC count was 411 9 /l. In early PMF, in which the bleeding rate was higher than in WHO-ET, these interactions did not reach the statistical significance. Of note, both in WHO-ET and in early PMF, aspirin-free patients with PLT count 41000 Â 10 9 /l showed no significant higher bleeding. 
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Discussion
The first novel finding of this analysis is the demonstration that a histological diagnosis of early PMF (rather than WHO-ET) is a significant and independent risk factor for major bleeding. This finding may be comparable to the results of other studies. In a post hoc analysis of 311 patients diagnosed with ET, according to the PVSG criteria, 5 that were mostly included in the prospective UK-PT1 trial, and received aspirin with either hydroxyurea or anagrelide, 10 increased bone marrow reticulin at presentation positively correlated with PLT counts (P ¼ 0.0001) and WBC (P ¼ 0.05), and predicted higher rates of major hemorrhage during follow-up (hazard ratio 2.0; P ¼ 0.05). 11 In this context, controversy persists whether those patients are more likely consistent with thrombocythemic manifestations of PMF. 12 In another recent retrospective study of 300 patients with a 're-assessed' diagnosis of WHO-ET, but without central histological bone marrow review, increased PLT count was independently associated with bleeding, whereas WBC 48.7 Â 10 9 /l showed an association of borderline statistical significance (IRR 3.8, P ¼ 0.09). 3 It is still a matter of discussion whether thrombocytosis and leukocytosis are simply markers of a more aggressive disease or have a pathogenetic role in inducing or extending hemorrhagic complications. The association of extreme thrombocytosis with an acquired von Willebrand disease is well documented, and the coagulopathy recovers with normalization of PLT count. 4 The role of leukocytosis is more intriguing, but neutrophils can release proinflammatory mediators of tissue destructions, such as matrix metalloproteases and elastases, which were reported to impair the blood-brain barrier after intracerebral hemorrhage, 13 or mediate toxin-induced intestinal ulceration and bleeding in animal models.
14 Whatever the pathogenetic mechanism is, a practical consequence of our observation is that aspirin therapy should be considered with caution in ET patients in whom the drug interacts synergistically with other risk factors. In fact, we have documented a synergistic interaction of aspirin with extreme thrombocytosis that per se was not found to be associated with increased bleeding. As expected, low-dose aspirin induced an additive bleeding effect when administered in WHO-ET patients with leukocytosis and in elderly patients grouped in high-risk category for thrombosis. In early PMF, in which the bleeding rate was significantly higher than in WHO-ET, a non-statistically significant trend of these correlations was seen, likely due to the inferior number of patients.
The second hitherto unreported outcome of this study is the estimate of incidence and risk factors for major bleeding in a population of strictly defined WHO-ET patients. In this entity, the bleeding rate was low (o1% pts/year) and mainly associated with aspirin use. This finding underlines caution in using aspirin in WHO-ET as primary prophylaxis in patients with extreme thrombocytosis. This notion is in agreement with previous data reporting an increased risk of major bleeding (IRR 5.4; P ¼ 0.004) in aspirin-treated ET patients at low thrombotic risk, and with a PLT count 41 000 000/mmc. In conclusion, our results demonstrate the need of an accurate morphological diagnosis of ET and early PMF for an appropriate evaluation of the bleeding risk, and a more precise identification of patients for whom aspirin therapy might not be indicated. 15 
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